Double blind randomized autologous stem cell trial treatment for peripheral arterial disease (PAD) with critical limb threatening ischemia

Peripheral vascular disease and Critical Limb Ischemia (CLI; also referred to as chronic limb threatening ischemia, CLTI) disease are caused by partial or complete blockage of blood vessels in the lower limbs. As the disease progresses, subjects deteriorate, and the limbs is subsequently impaired due to decreased blood flow in the small and microscopic blood vessels. Since the limbs do not receive sufficient blood supply, there is deterioration in limb function and wounds and lesions begin to form that will not heal. When further deterioration occurs, amputation may be required. This trial uses your own blood-derived stem and progenitor cells in a single treatment session in order to restore blood flow to the limb, heal wounds and prevent the need for amputation of the leg.